drugset / Trial / NCT02195817

Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care

NCT02195817

Phase 4 Terminated 378 enrolled H. Lundbeck A/S
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine the reduction in alcohol consumption in patients with alcohol dependence treated with 18 mg Selincro® as-needed use, in conjunction with continuous psychosocial support in primary care

Timeline

Start
2014-08
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalmefene Small molecule 18 mg Oral

Indications